News | August 22, 2014

Proton Therapy Offers Safe, Long-term Treatment for Hodgkin Lymphoma

Findings of the new American study correspond to the results of Proton Therapy Center Czech

Proton Therapy Safe Long-term Treatment Hodgkin Lymphoma Study Florida

August 22, 14 — The data by the University of Florida Proton Therapy Institute (UFPTI) shows a three-year relapse-free rate of 93 percent and a three-year event-free rate of 87 percent. "This study reinforces proton therapy as a safe alternative to the more conventional forms of radiation," said lead researcher Bradford S. Hoppe, M.D., radiation oncologist at the UF Proton Therapy Institute and assistant professor in the University of Florida College of Medicine department of radiation oncology.

The study continues to add to the mounting evidence supporting the use of proton radiation therapy for positive long-term treatment outcomes and quality of life of oncology patients. For instance, none of the patients developed grade three or higher toxicity during follow-up. The UFPTI specialists agreed that the use of proton therapy following chemotherapy in patients with Hodgkin lymphoma has a success rate similar to the conventional treatments with a reduction of radiation outside of the target area, or "involved-node," potentially reducing the risk of late effects caused by radiation.

The study tracked 15 patients between September 2009 and June 2013 with newly diagnosed Hodgkin lymphoma as they received involved-node proton therapy (INPT), which specifically targets initially involved lymph node(s) containing the Hodgkin lymphoma, after completing chemotherapy. Further, the study evaluated the radiation dose in the surrounding healthy tissue as a result of proton therapy compared with conventional treatments, called intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3DCRT).

Despite some success in treating patients with Hodgkin lymphoma, many patients suffer from late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. "Proton therapy, as opposed to similar conventional photon therapy, reduced the risk of long-term side effects by reducing or eliminating radiation doses to healthy tissue without compromising the cure rate," said lead researcher Bradford S. Hoppe.

The clinical results of Proton Therapy Center Czech, based on treatment of dozens of patients with Hodgkin lymphoma, correspond with the findings of the American study. “Proton therapy was approved for its clinical use in 1992 and has been used for treatment of selected stages of Hodgkin and non-Hodgkin lymphoma based on NCCN guidelines (National Comprehensive Cancer Network) since 2013,” adds doctor Jiri Kubes, Ph.D., the head of proton therapy at PTC Czech.

Comparison of treatment plans is the right and standard process used in radiation oncology, which enables us to foresee the possible risk of side effects and decide for the most appropriate treatment for each patient. This type of data is also important for examining the effectiveness of radiotherapy in general. Based on the international statistics, radiotherapy should be used for more than 50 percent of oncology patients during their treatment,” said Kubeš.

For more information: www.medicalnewstoday.com/releases/278648.php, www.lymphoma.eu.com

Related Content

Feature | Proton Therapy | October 04, 2018 | By Adam Conner-Simons
Investigating inside the human body often requires cutting open a patient or swallowing long tubes with built-in...
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Proton Treatment System
Feature | Proton Therapy | July 03, 2018 | By Jeff Zagoudis
The Alliance for Proton Therapy Access (APTA) released a national report in late May revealing the heavy emotional and...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...